Christineh N. Sarkissian

Christineh N. Sarkissian serves as the Chief Scientific Officer at Tandem Biotherapeutics, Inc. since December 2020 and concurrently holds the position of Science and Business Advisor at CaraVan Biologix. With extensive experience in the field, Christineh is a member of various scientific advisory boards, including the National PKU Alliance and The Canadian PKU Medical Working Group, focusing on improving PKU patient care. Christineh has also contributed to the National Institutes of Health as an external reviewer and has held key roles in preclinical development at Rubius Therapeutics. Christineh's educational background includes a PhD in Biochemical Genetics from McGill University and a Bachelor of Science in Genetics from York University, complemented by professional development from MIT xPRO and Bentley University.